Form 4: Schrodinger SVP & Controller Jenny Herman Reports Stock and Option Grants

Jenny Herman, SVP & Controller of Schrodinger, Inc., reports the grant of restricted stock units and stock options.

Summary

• Jenny Herman, SVP & Controller of Schrodinger, Inc., filed a Form 4 on March 5, 2024, reporting transactions related to the company's stock.
• On March 4, 2024, Herman was granted 7,313 restricted stock units (RSUs) and an option to purchase 14,625 shares of common stock at an exercise price of $25.24.
• The RSUs will vest in equal installments on March 5 of 2025, 2026, 2027 and 2028, contingent upon continued service with the company.
• The stock options vest 25% on March 4, 2025, and the remainder in equal monthly installments through March 4, 2028.
• Following these transactions, Herman beneficially owns 19,074 shares of common stock, including 13,313 unvested RSUs, and options to purchase 14,625 shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to executive compensation, and does not inherently convey positive or negative sentiment. It's a neutral disclosure of transactions.

Positives

• The grant of RSUs and stock options suggests the company is incentivizing its SVP & Controller, Jenny Herman, to remain with the company.
• The vesting schedules for both the RSUs and stock options are spread out over several years, aligning Herman's interests with the long-term performance of Schrodinger.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies like Schrodinger. It provides transparency into the equity-based compensation awarded to key personnel.

Comparison to Industry Standards

• Stock option and RSU grants are a common method of compensation for executives in the biotechnology and pharmaceutical industries.
• Companies like Relay Therapeutics, Recursion Pharmaceuticals, and Exscientia also utilize equity-based compensation to align executive incentives with shareholder value.
• The vesting schedules described are fairly standard, with multi-year vesting periods to encourage long-term commitment.

Stakeholder Impact

• The grant of equity to executives can align their interests with those of shareholders, potentially leading to increased company value.
• Employees may view equity grants as a positive sign of the company's commitment to its leadership.

Key Dates